BNT164a1

BIOLOGICAL3 trials

Sponsors

BioNTech SE

Conditions

Tuberculosis

Phase 1

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

CompletedNCT05537038

BioNTech SETuberculosis

Start: 2023-04-18End: 2025-12-08Updated: 2025-12-22

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

Active, not recruitingNCT05547464

BioNTech SETuberculosis

Start: 2023-07-31End: 2027-01-01Updated: 2026-03-18

Phase 2

A Phase Ib/IIa two-part, randomized, placebo-controlled, observer-blind, dose-finding evaluation trial to describe the safety, reactogenicity, and immunogenicity of two investigational vaccines against tuberculosis in BCG vaccinated, HIV-negative subjects and people living with HIV

Active, not recruitingPACTR202505818080160

BioNTech SETuberculosis

Start: 2025-03-03Target: 300Updated: 2025-06-24

Related Papers

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

2026-06-12